[Treatment of progressive and severe forms of @entity15 using a combination of antilymphocyte serum, @entity500 and XXXX . Clinical and biological results. Comparison with a control group treated with @entity500 and @entity229 only. 4-year follow-up].

@entity1 @entity500 @entity229 @entity56 @entity15
45 @entity1 were treated by combined application of antilymphocyte serum, @entity500 and @entity229 : a control group of such 22 @entity1 was besides treated by @entity500 and @entity229 only. The treatment by antilymphocyte serum included a four weeks initial treatment, and one year continuous treatment one infusion per week. @entity500 and @entity229 were given every day during the same time. @entity500 only was given during the three following year. The two groups were followed up during four years. This treatment was well accepted by @entity1 under strict technical survey conditions. Serum sickness was noted in 11 p. cent of the cases. The equine antiglobulin antibody titre, increased during the initial treatment, was connected with serum sickness or, when the treatment was continued, with the inefficacy of the treatment. Rosettes titre decreased in ten cases, no clinical correlation was possible. The complement, immune complexes, were normal before treatment with most of the observed @entity1 . The delayed @entity56 skin tests were negative after a month in 80 p. cent of the cases. The cerebrospinal fluid analysis, for the elements as well as for the rate of proteins and gammaglobulins, showed no significant variations before and after the treatment. The comparison with the control group showed a significant statistical difference as too the number of aggravated and improved @entity1 after the first year. When grouping together stable and improved @entity1 , the difference was statistically significant after the third year. The difference was not significant in years "two" or four. No difference in the frequency of the relapses could be noted, in the first year or the following three years. In spite of inconsistent results comparison showed favorable data after three years. The good results seemed due to the additional use of antilymphocyte serum. Such a treatment associating antilymphocyte serum to @entity500 and @entity229 is beneficial in evolutive, remittent and recent @entity15 . Through the length of the treatment remains difficult to determine, we conclude that it is really beneficial for such @entity1 .
